BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 23002041)

  • 1. Distinguishing benign from malignant mesothelial cells in effusions by Glut-1, EMA, and Desmin expression: an evidence-based approach.
    Kuperman M; Florence RR; Pantanowitz L; Visintainer PF; Cibas ES; Otis CN
    Diagn Cytopathol; 2013 Feb; 41(2):131-40. PubMed ID: 23002041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions.
    Hasteh F; Lin GY; Weidner N; Michael CW
    Cancer Cytopathol; 2010 Apr; 118(2):90-6. PubMed ID: 20209622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic value of BRCA1-associated protein-1, glucose transporter-1 and desmin expression in the discrimination between reactive mesothelial proliferation and malignant mesothelioma in tissues and effusions.
    Önder S; Özogul E; Koksal D; Sarinc Ulasli S; Firat P; Emri S
    Cytopathology; 2019 Nov; 30(6):592-600. PubMed ID: 31165505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Practical utility of insulin-like growth factor II mRNA-binding protein 3, glucose transporter 1, and epithelial membrane antigen for distinguishing malignant mesotheliomas from benign mesothelial proliferations.
    Chang S; Oh MH; Ji SY; Han J; Kim TJ; Eom M; Kwon KY; Ha SY; Choi YD; Lee CH; Lee Y; Jung SH
    Pathol Int; 2014 Dec; 64(12):607-12. PubMed ID: 25376377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic usefulness of EMA, IMP3, and GLUT-1 for the immunocytochemical distinction of malignant cells from reactive mesothelial cells in effusion cytology using cytospin preparations.
    Ikeda K; Tate G; Suzuki T; Kitamura T; Mitsuya T
    Diagn Cytopathol; 2011 Jun; 39(6):395-401. PubMed ID: 21574259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value of Glut-1 and Koc markers in the differential diagnosis of reactive mesothelial hyperplasia, malignant mesothelioma and pulmonary adenocarcinoma.
    Üçer Ö; Dağli AF; Kiliçarslan A; Artaş G
    Turk Patoloji Derg; 2013; 29(2):94-100. PubMed ID: 23661345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative immunohistochemical analysis of IMP3, GLUT1, EMA, CD146, and desmin for distinguishing malignant mesothelioma from reactive mesothelial cells.
    Minato H; Kurose N; Fukushima M; Nojima T; Usuda K; Sagawa M; Sakuma T; Ooi A; Matsumoto I; Oda M; Arano Y; Shimizu J
    Am J Clin Pathol; 2014 Jan; 141(1):85-93. PubMed ID: 24343741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytological differential diagnosis among adenocarcinoma, epithelial mesothelioma, and reactive mesothelial cells in serous effusions by immunocytochemistry.
    Su XY; Li GD; Liu WP; Xie B; Jiang YH
    Diagn Cytopathol; 2011 Dec; 39(12):900-8. PubMed ID: 20836004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic value of GLUT-1 in distinguishing malignant mesothelioma from reactive mesothelial cells: a meta-analysis.
    Zhong SC; Ao XJ; Yu SH
    Biomarkers; 2020 Mar; 25(2):157-163. PubMed ID: 31916460
    [No Abstract]   [Full Text] [Related]  

  • 10. Use of Anti-Noxa Antibody for Differential Diagnosis between Epithelioid Mesothelioma and Reactive Mesothelial Hyperplasia.
    Kushitani K; Amatya VJ; Mawas AS; Miyata Y; Okada M; Takeshima Y
    Pathobiology; 2016; 83(1):33-40. PubMed ID: 26735863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Usefulness of EMA, GLUT-1, and XIAP for the cytologic diagnosis of malignant mesothelioma in body cavity fluids.
    Shen J; Pinkus GS; Deshpande V; Cibas ES
    Am J Clin Pathol; 2009 Apr; 131(4):516-23. PubMed ID: 19289587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reactivity of six antibodies in effusions of mesothelioma, adenocarcinoma and mesotheliosis: stepwise logistic regression analysis.
    Dejmek A; Hjerpe A
    Cytopathology; 2000 Feb; 11(1):8-17. PubMed ID: 10714371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The diagnostic utility of D2-40, calretinin, CK5/6, desmin and MOC-31 in the differentiation of mesothelioma from adenocarcinoma in pleural effusion cytology.
    Hyun TS; Barnes M; Tabatabai ZL
    Acta Cytol; 2012; 56(5):527-32. PubMed ID: 23075894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of epithelial membrane antigen and silver-stained nucleolar organizer regions testing in the differential diagnosis of mesothelioma from benign reactive mesothelioses.
    Wolanski KD; Whitaker D; Shilkin KB; Henderson DW
    Cancer; 1998 Feb; 82(3):583-90. PubMed ID: 9452278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of desmin and N-cadherin in effusion cytology: a comparative study using established markers of mesothelial and epithelial cells.
    Davidson B; Nielsen S; Christensen J; Asschenfeldt P; Berner A; Risberg B; Johansen P
    Am J Surg Pathol; 2001 Nov; 25(11):1405-12. PubMed ID: 11684957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The diagnosis of malignant mesothelioma in effusion cytology: a reappraisal and results of a multi-institution survey.
    Paintal A; Raparia K; Zakowski MF; Nayar R
    Cancer Cytopathol; 2013 Dec; 121(12):703-7. PubMed ID: 24039177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2.
    Attanoos RL; Griffin A; Gibbs AR
    Histopathology; 2003 Sep; 43(3):231-8. PubMed ID: 12940775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Expression of glucose transporter protein 1 and desmin in reactive mesothelial hyperplasia and epithelioid malignant mesothelioma].
    Wei P; Jin ML; Zhao HY; Li X; Diao XL
    Zhonghua Bing Li Xue Za Zhi; 2013 Jul; 42(7):451-4. PubMed ID: 24246863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of methylthioadenosine phosphorylase and BRCA-associated protein 1 immunohistochemistry in the diagnosis of malignant mesothelioma in effusion cytology specimens.
    Berg KB; Churg AM; Cheung S; Dacic S
    Cancer Cytopathol; 2020 Feb; 128(2):126-132. PubMed ID: 31821740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peritoneal malignant mesothelioma (PMM), and primary peritoneal serous carcinoma (PPSC) and reactive mesothelial hyperplasia (RMH) of the peritoneum. Immunohistochemical and fluorescence in situ hybridisation (FISH) analyses.
    Kawai T; Tominaga S; Hiroi S; Ogata S; Nakanishi K; Kawahara K; Sonobe H; Hiroshima K
    J Clin Pathol; 2016 Aug; 69(8):706-12. PubMed ID: 26729015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.